Financial Data and Key Metrics Changes - The company reported $2.4 billion in revenue for Q3 2025, growing 1% on a reported basis and 4% on an organic operational basis, primarily driven by price as volume was flat [26][27] - Adjusted net income was $754 million, growing 5% on a reported basis and 9% on an organic operational basis [27][44] - Adjusted diluted EPS grew 7% operationally in the quarter and 12% on an organic operational basis [44] Business Line Data and Key Metrics Changes - The global companion animal portfolio posted revenue of $1.7 billion, growing 2% operationally, with the Simparica franchise contributing $356 million, growing 7% [27][31] - The livestock portfolio grew 10% on an organic operational basis, contributing $725 million in revenue, reflecting strong performance across segments and species [27][28] - The osteoarthritis pain franchise declined 11% operationally, with global Librela sales down 15% [13][27] Market Data and Key Metrics Changes - In the U.S., companion animal revenue was flat, while livestock grew 14% on an organic operational basis [29] - Internationally, revenue grew 3% on a reported basis and 6% on an organic operational basis, with companion animal growing 4% and livestock growing 8% [37][38] - The international Simparica franchise grew 22% operationally, with Simparica Trio growing 32% [39][40] Company Strategy and Development Direction - The company is focused on enhancing its U.S. commercial structure to better serve customers and improve agility, aiming for a leaner field organization [16][17] - Continued investment in manufacturing excellence and innovation is emphasized, with plans for new product launches and geographic expansions [15][20] - The company anticipates a major new market approval each year for the next several years, reinforcing its long-term growth trajectory [15][22] Management's Comments on Operating Environment and Future Outlook - Management noted that therapeutic visits in U.S. clinics have been declining, impacting new patient starts, but alternative channels are showing strong growth [63][64] - The company is optimistic about returning to growth in 2026, particularly in the livestock segment, which has shown resilience [55][96] - Management expressed confidence in the long-term growth potential of the business and the broader animal health market despite near-term challenges [46][96] Other Important Information - The company announced the retirement of Rob Holder, Head of R&D, and the appointment of Kevin Esch as his successor [22][23] - The company is implementing a multi-pronged strategy to return Librela to growth, focusing on education and awareness of osteoarthritis [14][80] Q&A Session Summary Question: What changed intra-quarter after raising guidance last quarter? - Management acknowledged deceleration in the back half of the year due to strong comps and macro impacts, particularly in U.S. clinics [50][51] Question: How is competition affecting the dermatology category? - Management noted that competitive dynamics have intensified, but they remain confident in their product positioning and market share [58][89] Question: What are the growth drivers for livestock moving forward? - Management highlighted sustainable demand for protein and urbanization as key growth drivers for livestock [96][97]

Financial Data and Key Metrics Changes - The company reported $2.4 billion in revenue for Q3 2025, growing 1% on a reported basis and 4% on an organic operational basis, primarily driven by price as volume was flat [18][29] - Adjusted net income was $754 million, reflecting a 5% increase on a reported basis and a 9% increase on an organic operational basis [18][29] - Adjusted gross margins improved to 71.6%, growing 90 basis points on a reported basis [28] Business Line Data and Key Metrics Changes - The global companion animal portfolio generated $1.7 billion in revenue, growing 2% operationally, with the Simparica franchise contributing $356 million, growing 7% [19][21] - The livestock portfolio grew 10% on an organic operational basis, contributing $725 million in revenue, with broad-based growth across segments and species [19][25] - The osteoarthritis (OA) pain franchise declined 11% operationally to $138 million, with Librela sales down 15% globally [8][19] Market Data and Key Metrics Changes - The U.S. market saw a 2% decline in revenue on a reported basis, while organic operational growth was 3% [21] - International revenue grew 3% on a reported basis and 6% on an organic operational basis, with companion animal growth at 4% and livestock growth at 8% [25][26] Company Strategy and Development Direction - The company is focused on enhancing its U.S. commercial structure to better serve customers and improve agility, aiming for a leaner field organization [12] - A multi-pronged strategy is being executed to return Librela to growth, including increasing awareness of OA as a serious disease and deepening education with specialists [9][48] - The company anticipates a major new market approval each year for the next several years, highlighting its robust innovation pipeline [10][16] Management's Comments on Operating Environment and Future Outlook - Management noted that growth moderated due to strong year-over-year comparisons and macro factors affecting vet clinic visits [5][15] - The company remains confident in its long-term growth trajectory, supported by a diversified portfolio and market-leading innovation [16][30] - Guidance for full-year organic operational revenue growth has been revised to 5.5%-6.5%, reflecting a more measured view of macro and operational trends [15][29] Other Important Information - The company announced the retirement of Rob Polzer, head of R&D, and the appointment of Kevin Esch as his successor [17] - The company is maintaining its reported diluted and adjusted diluted EPS guidance range of $5.90-$6.00 and $6.30-$6.40, respectively [29][30] Q&A Session Summary Question: What changed interquarterly after raising guidance last quarter? - Management noted anticipated deceleration in the second half of the year, with macro impacts particularly in U.S. clinics affecting therapeutic visits [31][32] Question: How is competition affecting the dermatology category? - Management acknowledged competitive dynamics but emphasized that the overall patient share gains from competitors have been limited [36][52] Question: What is the outlook for therapeutic visits recovery? - Management indicated that therapeutic visits have been down, impacting new patient starts, but expressed optimism for recovery as macro conditions improve [51][40] Question: How durable are the growth drivers in livestock? - Management expressed confidence in the sustainability of livestock growth, driven by increased demand for protein and population growth [56]

分组1 - Zoetis reported quarterly earnings of $1.7 per share, exceeding the Zacks Consensus Estimate of $1.62 per share, and showing an increase from $1.58 per share a year ago, resulting in an earnings surprise of +4.94% [1] - The company posted revenues of $2.4 billion for the quarter ended September 2025, slightly missing the Zacks Consensus Estimate by 0.35%, but showing a year-over-year increase from $2.39 billion [2] - Over the last four quarters, Zoetis has surpassed consensus EPS estimates four times and topped consensus revenue estimates three times [2] 分组2 - The stock has underperformed the market, losing about 11.4% since the beginning of the year, while the S&P 500 has gained 16.5% [3] - The company's earnings outlook, including current consensus earnings expectations for upcoming quarters, will be crucial for future stock performance [4] - The current consensus EPS estimate for the coming quarter is $1.48 on revenues of $2.42 billion, and for the current fiscal year, it is $6.35 on revenues of $9.5 billion [7] 分组3 - The Zacks Industry Rank indicates that the Medical - Drugs sector is currently in the top 36% of over 250 Zacks industries, suggesting that stocks in the top 50% outperform those in the bottom 50% by more than 2 to 1 [8] - The estimate revisions trend for Zoetis was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6]

Core Viewpoint - Zoetis has significantly reduced its full-year financial outlook, indicating challenges in the market and potential impacts on future performance [1] Financial Performance - The company has adjusted its revenue forecast, now expecting between $7.45 billion and $7.55 billion, down from a previous estimate of $7.55 billion to $7.65 billion [1] - Zoetis anticipates adjusted earnings per share (EPS) in the range of $3.05 to $3.15, a decrease from the earlier guidance of $3.15 to $3.25 [1] Market Challenges - The revision in outlook is attributed to various market pressures, including changes in demand and pricing dynamics within the veterinary pharmaceutical sector [1] - The company is facing increased competition and pricing pressures that are affecting its sales growth [1]

Financial Performance - Zoetis' Q3 revenue reached $24 billion, with organic operational growth of 4%[12] - Adjusted net income was $754 million, reflecting a 9% organic operational increase[12] - Adjusted diluted EPS stood at $170, demonstrating a 12% organic operational rise[12] Segment Highlights - The U S segment revenue totaled $13 billion, with 3% organic operational growth[24] - U S companion animal revenue remained flat at $11 billion[24] - U S livestock revenue saw a 14% organic operational increase, reaching $03 billion[24] - International segment revenue amounted to $11 billion, showing 6% organic operational growth[24] - International companion animal revenue grew 4% to $06 billion[24] - International livestock revenue increased by 8% to $05 billion[24] Updated Outlook - Zoetis revised its full-year 2025 organic operational revenue growth to 55%-65%[13] - The company maintained its adjusted diluted EPS guidance at $630-$640[13]

EXHIBIT 99.1 Zoetis Announces Third Quarter 2025 Results PARSIPPANY, N.J. – November 4, 2025 – Zoetis Inc. (NYSE:ZTS) today reported its financial results for the third quarter of 2025. The company reported revenue of $2.4 billion for the third quarter of 2025, an increase of 1% compared with the third quarter of 2024. On an organic operational basis, revenue for the third quarter of 2025 increased 4% compared with the third quarter of 2024. Net income for the third quarter of 2025 was $721 million, or $1.6 ...

Core Insights - Zoetis Inc. is a leading global animal health company set to release its Q3 2025 earnings on November 4, 2025, with Wall Street anticipating EPS of $1.62 and revenue of approximately $2.41 billion [1][2] Financial Performance - The company is expected to surpass earnings estimates due to strong demand for companion animal products like Simparica Trio and Apoquel, indicating robust performance in this segment [2][6] - A year-over-year increase in earnings is projected, attributed to higher revenues for the quarter ending September 2025, which could positively impact stock price [3][6] Financial Metrics - Zoetis has a price-to-earnings (P/E) ratio of 24.60, indicating investors are willing to pay $24.60 for every dollar of earnings [4][6] - The price-to-sales ratio is 6.82, and the enterprise value to sales ratio is 7.39, reflecting the market's valuation of its revenue and sales [4] - The company maintains a debt-to-equity ratio of 1.36, suggesting a balanced use of debt and equity in financing, and a current ratio of 1.76 indicates it can comfortably cover short-term liabilities [5][6] - An earnings yield of 4.07% showcases the company's profitability based on earnings [5]

Core Viewpoint - Zoetis Inc. announces the retirement of Dr. Rob Polzer at the end of 2025 and the appointment of Dr. Kevin Esch as the new President of Research & Development starting January 1, 2026, highlighting a planned succession to maintain momentum in innovation within the animal health sector [1][2][3]. Leadership Transition - Dr. Rob Polzer will retire on February 28, 2026, after a decade of contributions to veterinary medicine and innovation, and will serve as a scientific advisor through 2026 to ensure a smooth transition [1][3]. - Dr. Kevin Esch, currently Senior Vice President of Global Therapeutics, will take over the role, bringing over 10 years of experience as a veterinarian and a strong background in research and development [2][7]. Innovation and Growth Strategy - Zoetis is committed to advancing animal care globally through a robust innovation pipeline, with expectations for significant product approvals in major markets annually for the next several years [4]. - The company has introduced 17 blockbuster products and over 2,000 new products and lifecycle innovations in the past 12 years, investing more in R&D than any other animal health company [4]. Upcoming Events - An Innovation Webcast is scheduled for December 2, 2025, to update investors and the public on Zoetis' innovative pipeline and strategic approach to addressing unmet needs in the industry [5]. Contributions of Dr. Rob Polzer - Under Dr. Polzer's leadership, Zoetis has launched several groundbreaking products and established new markets, significantly transforming standards of care in animal health [10][11]. - His tenure has been marked by a focus on scientific rigor and collaboration, leading to advancements in therapies, vaccines, and digital solutions [10][11]. Background of Dr. Kevin Esch - Dr. Esch has held various influential roles within Zoetis since joining in 2014, overseeing global research and development efforts and managing key acquisitions [7][8]. - His educational background includes a Doctor of Veterinary Medicine, a Master of Public Health, and a Ph.D. in Immunobiology, reflecting a strong commitment to veterinary medicine [8][9].

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

Core Insights - Zoetis (ZTS) stock is noteworthy due to its high margins, indicating strong pricing power and cash generation capabilities, currently available at a discounted price [2][3] Financial Performance - Revenue growth for Zoetis was 5.3% over the last twelve months and averaged 5.5% over the past three years, indicating stable but not rapid growth [8] - The company reported an operating cash flow margin of approximately 31.2% and an operating margin of 37.5% for the last twelve months [8] - Long-term profitability metrics show an operating cash flow margin of about 28.7% and an average operating margin of 36.6% over the past three years [8] - ZTS stock is currently trading at a price-to-sales multiple of 6.8, reflecting a 24% discount compared to one year ago [8] Market Position - Zoetis provides a range of medicines, vaccines, and diagnostic products for animal health, targeting various livestock species to prevent diseases affecting respiratory, gastrointestinal, and reproductive systems [4]